Imolope

Loperamide Hydrochloride, the active ingredient in Imolope, is an opioid antidiarrheal presented as an oral tablet for oral use. It reduces intestinal motility and water loss, helping manage acute and chronic diarrhea as well as diarrhea‑predominant irritable bowel syndrome in adults.

GNH USA supplies Imolope as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support.

Imolope (loperamide hydrochloride) is used to treat diarrheal conditions by slowing gastrointestinal transit.

- Acute diarrhea: reduces stool frequency and improves consistency in sudden‑onset watery stools. - Chronic diarrhea: helps control persistent loose stools associated with various gastrointestinal disorders. - Irritable bowel syndrome with diarrhea: alleviates bowel urgency and frequency in IBS‑D patients.

Loperamide may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Constipation: hard stools or reduced bowel movements. - Abdominal cramps: mild to moderate discomfort. - Nausea: feeling of sickness or urge to vomit. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Severe constipation: risk of bowel obstruction. - Toxic megacolon: extreme dilation of the colon. - Cardiac arrhythmias: irregular heart rhythm, especially with high doses. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

When using Imolope, certain precautions should be observed to ensure safe and effective therapy.

- Dosage adjustment: reduce dose in patients with hepatic impairment. - Underlying disease: avoid in suspected infectious diarrhea caused by invasive bacteria. - Fluid balance: maintain adequate hydration to prevent electrolyte disturbances. - Age considerations: use with caution in elderly patients due to slower gut motility. - Drug interactions: review concomitant medications that may affect cardiac conduction. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Loperamide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - P-glycoprotein inhibitors (e.g., quinidine, ritonavir): may increase systemic loperamide levels and risk of cardiotoxicity. - CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): can raise plasma concentrations. - Other opioid agonists: additive central opioid effects are unlikely but may increase constipation.

Moderate Interactions (Monitor Closely): - Antidiarrheal agents (e.g., diphenoxylate): combined effect may cause excessive slowing of gut motility. - Anticholinergic drugs: may enhance anticholinergic burden leading to constipation. - QT‑prolonging drugs (e.g., macrolide antibiotics): monitor ECG for arrhythmia risk.